Citadel Advisors’s Korro Bio KRRO Stock Holding History

Citadel Advisors’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.91M	Sell	168,700 -110,300	-40%	-$1.21M	﹤0.01%	6155
2025 Q4	$2.23M	Buy	+279,000	New	+$6.52M	﹤0.01%	5703
2023 Q3	–	Sell	-78	Closed	-$1.35K	–	14730
2023 Q2	$1.35K	Sell	78 -1,226	-94%	-$23.8K	﹤0.01%	13947
2023 Q1	$32.8K	Buy	1,304 +1,244	+2,073%	+$142K	﹤0.01%	12641
2022 Q4	$11.6K	Buy	+60	New	+$6.17K	﹤0.01%	13563
2021 Q4	–	Sell	-432	Closed	-$153K	–	14325
2021 Q3	$153K	Sell	432 -588	-58%	-$231K	﹤0.01%	12358
2021 Q2	$508K	Sell	1,020 -3,210	-76%	-$1.57M	﹤0.01%	10028
2021 Q1	$2.01M	Buy	4,230 +3,998	+1,723%	+$7.77M	﹤0.01%	6371
2020 Q4	$409K	Buy	+232	New	+$306K	﹤0.01%	8516

Other funds holding KRRO

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's KRRO Position: Q1 2026 in Review

Citadel Advisors reduced its Korro Bio (KRRO) stake by 47% in Q1 2026, selling an estimated $302K and leaving 30,914 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #10123.

Citadel Advisors first reported a position in KRRO in Q4 2019 and has held it in 22 quarters since. The position peaked at $46.4M in Q1 2024. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

Citadel Advisors held 30,914 shares of Korro Bio worth $350K as of Q1 2026.
Citadel Advisors sold 27,415 Korro Bio shares in Q1 2026, an estimated $302K.
Korro Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10123 holding.
Citadel Advisors first reported a position in Korro Bio in Q4 2019 and has held it in 22 quarters since.
Citadel Advisors's Korro Bio position peaked at $46.4M in Q1 2024.
99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.